DLL3-Targeted PET/CT in Small Cell Lung Cancer
Recruiting · NCT07677787 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
What this trial is about
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adult patients (aged 18 years or older);
- Patients with suspected, newly diagnosed, and previously treated small cell lung cancer(supporting evidence may include imaging findings and pathology report);
- Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
- Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;
Exclusion criteria
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
- Inability to complete PET/CT imaging.
Where it is running
1 location listed.
- The First Affiliated Hospital of Xiamen University - Xiamen, Fujian, China